Past Event Category: Cancer Biology Seminar
-
Nov 20Cancer Biology Seminar Series: Marina Sharifi, MD, PhD
1345 HSLC
Leveraging liquid biopsies to track mechanisms of targeted therapy resistance in breast and prostate cancer Marina Sharifi, MD, PhD Assistant Professor, Hematology, Medical Oncology and Palliative Care University of Wisconsin–Madison
-
Nov 13Cancer Biology Seminar Series: Ping Chi, MD, PhD
1345 HSLC
Harnessing innate immunity in sarcoma Ping Chi, MD, PhD Associate Professor, Cell & Developmental Biology Weill Cornell School of Medicine Memorial Sloan Kettering Cancer Center
-
Nov 6Cancer Biology Seminar Series: Nicholas Wallace, PhD
1345 HSLC
Targeting HPV Oncogene-Induced Alterations in Cervical Cancer Nicholas Wallace, PhD Professor, Division of Biology Johnson Cancer Research Center Kansas State University
-
Oct 30Cancer Biology Seminar Series: Dechen Lin, PhD
1345 HSLC
Organoid modeling cancer evolution and drug response Dechen Lin, PhD Assistant Professor, Herman Ostrow School of Dentistry University of Southern California
-
Oct 23Cancer Biology Seminar Series: Binhua Zhou, MD, PhD
1345 HSLC
TBD Binhua Zhou, MD, PhD Professor, Molecular and Cellular Biochemistry University of Kentucky School of Medicine
-
Oct 16Cancer Biology Seminar Series: Mohamed Abazeed, MD, PhD
1345 HSLC
Harnessing computation to guide more individualized cancer therapies to the lung Mohamed Abazeed, MD, PhD Associate Professor, Radiation Oncology Northwestern University
-
Oct 9Cancer Biology Seminar Series: Charles Perou, PhD
1345 HSLC
Quantitative Medicine for Breast Cancer Patients Charles Perou, PhD Professor of Molecular Oncology University of North Carolina School of Medicine
-
Oct 2Cancer Biology Seminar Series: Todd Stukenberg, PhD
1345 HSLC
Mechanisms of Chromosomal Instability in Breast Cancer Todd Stukenberg, PhD Professor, Biochemistry and Molecular Genetics University of Virginia School of Medicine
-
Sep 25Cancer Biology Seminar Series: Dave Vereide, PhD
1345 HSLC
Arming induced pluripotent stem cells with a synthetic receptor enables the scalable manufacture of highly cytotoxic lymphocytes for “off-the-shelf” cancer immunotherapies Dave Vereide, PhD Principal Scientist Umoja Biopharma
-
Sep 18Cancer Biology Seminar Series: Dusty Deming, MD
1345 HSLC
Future Strategies for Precision Targeting of Cancer Therapeutics Dusty Deming, MD Associate Professor of Hematology-Oncology University of Wisconsin–Madison